Immunity and Type 1 Diabetes

 

The Immunity and Type 1 Diabetes theme is committed to finding low-risk immunotherapies able to preserve beta cell function in type 1 diabetes and introduce these therapies into clinic care. We collaborate with colleagues across the UK in the Type 1 Diabetes Immunotherapy Consortium to conduct clinical trials in adults and children with new-onset type 1 diabetes and develop new approaches to beta cell preservation (www.type1diabetesresearch.org.uk). Studies range from first-in-man to phase III. In this area we work closely with partners including Diabetes UK, the Juvenile Diabetes Research Foundation (JDRF), SAIL and the University of Bristol. We are developing large scale data linkage projects to define the outcomes for patients with type 1 diabetes and the potential benefits of beta cell preservation. 

Aim

  • To lead on clinical trials in diabetes immunotherapy across the UK

 

Objectives

  • lead on clinical trials and staff training in diabetes immunotherapy across 15 centres in the UK (“Type 1 Diabetes UK Immunotherapy Consortium”)
  • combine with the DRN England ADDRESS-2 research network identifying subjects with newly-diagnosed type 1 diabetes from 122 centres across the UK.